The European IVDR continues to challenge MedTech manufacturers with inconsistent interpretations and sudden shifts in compliance requirements. This episode dives into a recent and critical development: the "silent reclassification" of certain diagnostic software, which is forcing companies to pull products from the market and re-evaluate their entire regulatory strategy.

We explore a case study of a cancer risk-scoring software company that found its product non-compliant overnight due to a new interpretation by a single EU authority. This unexpected change has triggered a costly, year-long scramble for recertification, exposing the severe financial and operational risks of regulatory fragmentation in the EU. This is a must-listen for any company with software as a medical device in Europe.

This week's key takeaways:

- What is the "silent reclassification" threatening IVD software in Europe?

- Why is a subtle rule interpretation causing massive budget and timeline overruns?

- How can your technical file become non-compliant without any change in regulation?

- Which specific types of diagnostic and patient-data software are most at risk?

- Is the EU market becoming too difficult for innovative digital health startups?

- What are the key elements of a regulatory strategy that can withstand these shocks?

- What is the single biggest mistake to avoid when your device classification is challenged?

- How do you prepare for notified body audits when your risk class suddenly changes?

To learn more about building a resilient global regulatory strategy, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and a comprehensive medical device database, visit https://pureglobal.ai/.